Newlink Genetics Corp (NLNK): Ernest Iii Talarico , director of Newlink Genetics Corp purchased 4,065 shares on Jun 6, 2016. The Insider buying transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were purchased at $12.32 per share for a total value of $50,080.80 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 11, 2016, Charles J. Jr. Link (Chairman of the Board and CEO) sold 10,000 shares at $20.02 per share price.On Jan 6, 2016, Brian Wiley (VP of Business Development) sold 1,295 shares at $34.73 per share price.Also, On Jan 6, 2016, John B Iii Henneman (EVP, Chief Financial Officer) sold 175 shares at $35.74 per share price.On Jan 6, 2016, Carl W. Langren (Principal Accounting Officer) sold 1,095 shares at $35.01 per share price.
Shares of NewLink Genetics Corp (NLNK) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.61 points or -4.98% at $11.63 with 6,28,361 shares getting traded. Post opening the session at $12.05, the shares hit an intraday low of $11.59 and an intraday high of $12.298 and the price vacillated in this range throughout the day. The company has a market cap of $336 M and the number of outstanding shares has been calculated to be 2,88,97,411 shares. The 52-week high of NewLink Genetics Corp is $56.16 and the 52-week low is $9.23.
Company has been under the radar of several Street Analysts.NewLink Genetics Corp is Downgraded by Sun Trust Rbsn Humphrey to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 11, 2016.NewLink Genetics Corp is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 23 from a previous price target of $63 . The Rating was issued on May 10, 2016.NewLink Genetics Corp is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 20 from a previous price target of $52 . The Rating was issued on May 10, 2016.NewLink Genetics Corp is Initiated by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $27. The Rating was issued on Mar 23, 2016.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system’s tolerance to cancer by inhibiting the indoleamine-(2 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.